Multiple CCR1 inhibitors have been developed for the treatment of a variety of diseases such as rheumatoid arthritis and multiple sclerosis, and, having proceeded through phase 1 and 2 clinical trials, have been found safe for use in humans15. Here, CCR1 is linked to multiple sclerosis.